Select Page

The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact. 

A critical partner within one of the world’s largest and most complex public-private product development partnerships—which brings together the Bill & Melinda Gates Foundation, the US National Institutes of Health, Sanofi Pasteur, GSK, the US Military, the HIV Vaccine Trials Network and the South African Government—Shift Health has been working over the course of a multi-year effort to achieve consensus among stakeholders on critical strategic decisions, align on product development plans, prepare for program risks and outcomes, and design vaccine access strategies to ensure that a successful vaccine achieves maximum public health benefit as quickly as possible.

Shift Health’s vital strategic and program management support is helping the P5 deliver on its mission to alleviate the burden of HIV/AIDS in Sub-Saharan Africa and beyond.

Shift Health helps crystallize thinking and brings clarity to difficult conversations.

DIRECTOR, Global Health Funding Organization